Danish pharmaceutical company Novo Nordisk said on Tuesday it has decided to stop its activities within inflammatory disorders and only focus on the treatment and prevention of diabetes and obesity. The decision follows a discontinuation for the company's most advanced drug candidate within the area, a drug used to treat rheumatoid arthritis and known as anti-IL-20, announced on Aug. 7 together with its with second quarter results. "The discontinuation of anti-IL-20 delays our earliest possible entrance into the market for anti-inflammatory therapeutics to the late 2020s," Chief Science Officer Mads Krogsgaard Thomsen said in a statement. Novo Nordisk said 400 employees would be affected by the decision but that it hoped to offer other positions within the company to more than half of those.
via Health News Headlines - Yahoo News http://ift.tt/1tq1pAo
No comments:
Post a Comment